Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.

ABSTRACT: Assess the pharmacodynamics of lixisenatide once daily (QD) versus liraglutide QD in type 2 diabetes insufficiently controlled on metformin.In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10?µg weeks 1-2, then 20?µg; n?=?77) or liraglutide QD (0.6?mg week 1, 1.2?mg week 2, then 1.8?mg; n?=?71) 30?min before breakfast. Primary endpoint was change in postprandial plasma glucose (PPG) exposure from baseline to day 28 during a breakfast test meal.Lixisenatide reduced PPG significantly more than liraglutide [mean change in AUC(0:30-4:30h) : -12.6 vs. -4.0?h·mmol/L, respectively; p?

SUBMITTER: Kapitza C 

PROVIDER: S-EPMC3752965 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature